Head to Head Review: Silo Pharma (NASDAQ:SILO) vs. AquaBounty Technologies (NASDAQ:AQB)
by Jessica Moore · The Cerbat GemAquaBounty Technologies (NASDAQ:AQB – Get Free Report) and Silo Pharma (NASDAQ:SILO – Get Free Report) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their earnings, risk, profitability, valuation, analyst recommendations, dividends and institutional ownership.
Insider & Institutional Ownership
8.9% of AquaBounty Technologies shares are held by institutional investors. Comparatively, 5.6% of Silo Pharma shares are held by institutional investors. 1.0% of AquaBounty Technologies shares are held by insiders. Comparatively, 2.2% of Silo Pharma shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.
Profitability
This table compares AquaBounty Technologies and Silo Pharma’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| AquaBounty Technologies | N/A | -54.51% | -16.67% |
| Silo Pharma | -6,726.39% | -88.40% | -70.03% |
Analyst Ratings
This is a summary of current recommendations for AquaBounty Technologies and Silo Pharma, as reported by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| AquaBounty Technologies | 1 | 0 | 0 | 0 | 1.00 |
| Silo Pharma | 1 | 0 | 0 | 0 | 1.00 |
Risk & Volatility
AquaBounty Technologies has a beta of 1.39, meaning that its stock price is 39% more volatile than the S&P 500. Comparatively, Silo Pharma has a beta of 0.63, meaning that its stock price is 37% less volatile than the S&P 500.
Earnings and Valuation
This table compares AquaBounty Technologies and Silo Pharma”s top-line revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| AquaBounty Technologies | $2.47 million | 1.96 | -$18.49 million | ($1.19) | -0.79 |
| Silo Pharma | $70,000.00 | 94.42 | -$4.23 million | ($6.45) | -0.95 |
Silo Pharma has lower revenue, but higher earnings than AquaBounty Technologies. Silo Pharma is trading at a lower price-to-earnings ratio than AquaBounty Technologies, indicating that it is currently the more affordable of the two stocks.
Summary
AquaBounty Technologies beats Silo Pharma on 8 of the 11 factors compared between the two stocks.
About AquaBounty Technologies
AquaBounty Technologies, Inc., a biotechnology company, operates in the aquaculture industry in the United States and Canada. The company engages in genetic, genomic, and fish health and nutrition research activities. It also operates salmon farms using proprietary technology. In addition, the company offers AquAdvantage Salmon, a genetically engineered Atlantic salmon for human consumption; and sells conventional Atlantic salmon, salmon eggs, fry, and byproducts. The company was formerly known as Aqua Bounty Farms, Inc. and changed its name to AquaBounty Technologies, Inc. in June 2004. AquaBounty Technologies, Inc. was incorporated in 1991 and is headquartered in Harvard, Massachusetts.
About Silo Pharma
Silo Pharma Inc. operates as a developmental stage biopharmaceutical company. The company is developing therapeutics that address underserved conditions, including stress-induced psychiatric disorders, chronic pain conditions, and central nervous system (CNS) diseases. It focuses on developing traditional therapies and psychedelic treatments in formulations and drug delivery systems. The company’s lead program, SPC-15, is an intranasal treatment targeting PTSD and stress-induced anxiety disorders. It is also developing SP-26, a time-release ketamine-loaded implant for fibromyalgia and chronic pain relief. In addition, the company’s two preclinical programs comprise SPC-14, an intranasal compound for the treatment of Alzheimer’s disease, and SPU-16, a CNS-homing peptide targeting multiple sclerosis (MS). The company’s research and development programs are conducted through collaborations with Columbia University and the University of Maryland, Baltimore. The company was formerly known as Uppercut Brands, Inc. and changed its name to Silo Pharma, Inc. in September 2020. Silo Pharma, Inc. was incorporated in 2010 and is based in Sarasota, Florida.